Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia
- 306 Downloads
Bivalirudin, a direct thrombin inhibitor, is indicated for patients with suspected heparin-induced thrombocytopenia (HIT) with anticipated percutaneous coronary intervention (PCI). Data is limited on dose selection among patients with renal insufficiency, particularly with prolonged infusion durations. The study cohort comprised 73 patients with renal dysfunction who received bivalirudin for suspected HIT with or without acute coronary syndrome. We reviewed individual pharmacy and medical records for laboratory and bivalirudin dosing information, medical comorbidities, and adverse clinical outcomes during administration. When estimated glomerular filtration rate (eGFR) was calculated by the Cockcroft–Gault (CG; ml/min) formula, the average bivalirudin dose (mg/kg/h) achieving a therapeutic activated partial thromboplastin time (aPTT) was 0.07 ± 0.04, 0.15 ± 0.08, and 0.16 ± 0.07 for patients with eGFR between 15–30, 31–60, and >60, respectively. When eGFR was calculated by the modification of diet in renal disease (MDRD; ml/min/1.73 m2) formula, the average bivalirudin dose achieving a therapeutic aPTT was 0.07 ± 0.04, 0.12 ± 0.07, and 0.20 ± 0.07 for patients with eGFR between 15–30, 31–60, >60, respectively. The difference between the dose achieving a therapeutic aPTT for patients with eGFR >60 when calculated by MDRD versus CG was completely abolished when obese patients were excluded from the CG cohort. The results of our series of patients with renal dysfunction receiving prolonged duration of bivalirudin in the setting of acute coronary syndrome (ACS) suggests that dose adjustment is safe and should be considered for patients with moderate to severe renal impairment (eGFR < 60 ml/min/1.73 m2).
KeywordsBivalirudin Renal insufficiency Heparin-induced thrombocytopenia
We would like to acknowledge the contributions of Dr. Christopher Meduri and Dr. Christopher Huff for their assistance with data collection and obtaining IRB approval.
- 1.Bartholomew J (2004) Bivalirudin for the treatment of heparin induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia, 3rd edn. Marcel Dekkar, New YorkGoogle Scholar
- 4.Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7):853–863PubMedCrossRefGoogle Scholar
- 5.Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355(21):2203–2216PubMedCrossRefGoogle Scholar
- 6.Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ (2005) Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95(5):581–585. doi: 10.1016/j.amjcard.2004.11.003 PubMedCrossRefGoogle Scholar
- 8.Angiomax [package insert] (2002) The Medicines Company, ParsippanyGoogle Scholar
- 14.Runyan CL, Cabral KP, Riker RR, Redding D, May T, Seder DB, Savic M, Hedlund J, Abramson S, Fraser GL (2011) Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. Pharmacotherapy 31(9):850–856. doi: 10.1592/phco.31.9.850 PubMedCrossRefGoogle Scholar
- 15.Robson R (2000) The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 12 Suppl:F33–F36Google Scholar
- 18.Michaels AD, Spinler SA, Leeper B, Ohman EM, Alexander KP, Newby LK, Ay H, Gibler WB (2010) Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation 121(14):1664–1682. doi: 10.1161/CIR.0b013e3181d4b43e PubMedCrossRefGoogle Scholar
- 22.Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ (2004) Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93(9):1092–1096. doi: 10.1016/j.amjcard.2004.01.033 PubMedCrossRefGoogle Scholar
- 23.Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Hall PM (2005) Performance of the Cockcroft–Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 46(2):242–252. doi: 10.1053/j.ajkd.2005.04.023 PubMedCrossRefGoogle Scholar
- 24.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002) Am J Kidney Dis 39(2 Suppl 1):S1–266Google Scholar